PAHC vs DBVT

Phibro Animal Health Corporation (PAHC) offers the better valuation at 49.

3x trailing P/E (19. 3x forward), making it the more compelling value choice. Analysts rate Phibro Animal Health Corporation (PAHC) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Phibro Animal Health Corporation (PAHC) delivered a total return of +136.

4%, compared to -66. 6% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: PAHC returned +207. 3% versus DBVT's -86. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), DBV Technologies S.

A. (DBVT) is the lower-risk stock at 1. 26β versus Phibro Animal Health Corporation's 1. 38β — meaning PAHC is approximately 10% more volatile than DBVT relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 3% for Phibro Animal Health Corporation — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to -347.

5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Phibro Animal Health Corporation (PAHC) is the more profitable company, earning 3.

7% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 3. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PAHC leads at 8. 5% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — PAHC leads at 30. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DBVT: 130.

5% to $46. 33.

In this comparison, PAHC (0.

8% yield) pays a dividend. DBVT does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Phibro Animal Health Corporation (PAHC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0.

8% yield, +207. 3% 10Y return). Both have compounded well over 10 years (PAHC: +207. 3%, DBVT: -86. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PAHC is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock. PAHC pays a dividend while DBVT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.